南新制药连跌5天，大成基金旗下1只基金位列前十大股东

Company Overview - Nanjing New Pharmaceutical Co., Ltd. focuses on the research, production, and marketing of chemical drugs, aiming to develop new and special drugs for major and sudden diseases to better meet clinical medication needs and support the "Healthy China" strategy [1] Financial Performance - Nanjing New Pharmaceutical has experienced a decline in stock price, with a cumulative drop of -18.50% over five consecutive trading days as of August 8 [1] - The Dachen Jingheng Mixed A Fund, managed by Dachen Fund, remains one of the top ten shareholders of Nanjing New Pharmaceutical, with a year-to-date return of 32.19%, ranking 477th among 4,504 similar funds [1] Fund Management - The fund manager of Dachen Jingheng Mixed A is Su Bingyi, who holds a master's degree in economics from Tsinghua University and has extensive experience in fund management since joining Dachen Fund in 2008 [4][5] - Su Bingyi has managed various funds over his career, including the Dachen Core Dual Power Mixed Fund and the Dachen Health Industry Stock Fund, showcasing a diverse portfolio management experience [4][5]